Neumora Therapeutics (NMRA) Resumen de Acciones
Neumora Therapeutics, Inc. es una empresa biofarmacéutica en fase clínica dedicada al desarrollo de tratamientos terapéuticos para enfermedades cerebrales, neuropsiquiátricas y neurodegenerativas en Estados Unidos. Saber más
| Puntuación del snowflake | |
|---|---|
| Valoración | 0/6 |
| Crecimiento futuro | 0/6 |
| Rendimiento pasado | 0/6 |
| Salud financiera | 3/6 |
| Dividendos | 0/6 |
Análisis de riesgos
+ 2 riesgos adicionales
NMRA Community Fair Values
Create NarrativeSee what 10 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Competidores de Neumora Therapeutics, Inc.
Historial de precios y rendimiento
| Precios históricos de las acciones | |
|---|---|
| Precio actual de la acción | US$1.04 |
| Máximo en las últimas 52 semanas | US$3.65 |
| Mínimo de 52 semanas | US$0.83 |
| Beta | 2.74 |
| Cambio en 1 mes | -35.00% |
| Variación en 3 meses | -33.33% |
| Cambio de 1 año | -31.58% |
| Variación en 3 años | -92.97% |
| Variación en 5 años | n/a |
| Variación desde la OPV | -93.60% |
Noticias y actualizaciones recientes
Recent updates
NMRA: Early Neuroscience Pipeline Will Become Central Driver After Trial Setback
Analysts have cut their average price target for Neumora Therapeutics from about $8.91 to roughly $6.53, reflecting the removal of navacaprant from their models after the KOASTAL-2 and KOASTAL-3 trial setbacks, partially offset by interest in the remaining pipeline and expected cost savings. Analyst Commentary Recent Street research on Neumora Therapeutics centers on the decision to discontinue navacaprant after the KOASTAL-2 and KOASTAL-3 outcomes and how that change affects valuation, cost structure, and focus on the earlier stage pipeline.
NMRA: Early Pipeline And Cost Cuts Will Drive Future Rebound Potential
Neumora Therapeutics' analyst price targets have been cut sharply, with several firms lowering their views into a $4 to $7 range after removing navacaprant from their models following the KOASTAL-2 and -3 Phase 3 failures and incorporating cost savings from a 35% workforce reduction, alongside continued interest in the remaining early-stage pipeline. Analyst Commentary Recent research on Neumora Therapeutics reflects a reset in expectations after the KOASTAL-2 and -3 outcomes, with price targets now clustered in the mid-single digits and coverage largely maintained.Multiple Late Stage Brain Disease Programs Will Drive Long Term Upside Potential
Catalysts About Neumora Therapeutics Neumora Therapeutics develops brain penetrant medicines targeting novel mechanisms for psychiatric, neurologic and metabolic diseases. What are the underlying business or industry changes driving this perspective?CNS And Obesity Pipeline Will Create Long Term Value As Late Stage Data Emerges
Catalysts About Neumora Therapeutics Neumora Therapeutics focuses on developing brain penetrant medicines for neuropsychiatric, neurodegenerative, and metabolic diseases. What are the underlying business or industry changes driving this perspective?Neumora Therapeutics: Downgrading After Navacaprant Development Setback
Summary Neumora Therapeutics is downgraded from 'Strong Buy' to 'Hold' following KOASTAL-1's failure in the MDD primary endpoint. KOASTAL-2 and KOASTAL-3 studies for navacaprant in MDD have increased enrollment; topline data is expected in Q2 2026, but success remains uncertain. NMRA-511 showed a promising signal in phase 1b for Alzheimer's Disease agitation, with an enhanced effect in patients with elevated anxiety. Phase 2 study initiation for NMRA-511 in AD agitation is not expected until Q1 2027, making near-term value realization unlikely despite large unmet market need. Read the full article on Seeking AlphaNeumora Therapeutics: Tanking On Disastrous MDD Data, Bounce Back Unlikely
Summary Neumora Therapeutics' lead candidate, navacaprant, failed to meet primary and secondary endpoints in its Phase 3 KOASTAL-1 study for major depressive disorder, causing an 80% stock drop yesterday. Despite significant funding and a “promising” Phase 2 study, concerns about endpoint changes and lack of peer-reviewed data undermine confidence in navacaprant's efficacy. With two more Phase 3 studies pending, the market may have overreacted, but the likelihood of a turnaround remains slim given current evidence. Neumora's other assets and cash reserves offer limited near-term revenue prospects, making a contrarian bet on navacaprant risky and ill-advised. Read the full article on Seeking AlphaNeumora: Koastal-1 Readout For MDD Treatment Is First Study On Deck
Summary Neumora Therapeutics is set to release data from the phase 3 KOASTAL-1 study using Navacaprant for the treatment of patients with MDD by the end of 2024; other data in 2025. Navacaprant showed significant efficacy in a phase 2 study for MDD and is also being tested for bipolar depression, with phase 2 data expected in late 2025. Neumora has $341.3 million in cash, enough to fund operations until mid-2026, minimizing near-term dilution risk unless management opts otherwise. Key NMRA risks include the potential failure of KOASTAL-1 to meet primary endpoints and uncertainty in Navacaprant's efficacy for bipolar depression and NMRA-511 for Alzheimer's agitation. Read the full article on Seeking AlphaNeumora Therapeutics: A Story Of A Class II Biotech
Summary Neumora Therapeutics' lead asset, Navacaprant, shows weak efficacy in phase 2 trial, casting doubt on its success in upcoming phase 3 trials. The company's AI-driven precision medicine claims have not materialized in clinical trial designs, undermining their differentiation strategy. Valuation models suggest Neumora's stock is overvalued, with a fair valuation significantly lower than the current market price. Read the full article on Seeking AlphaWe're Hopeful That Neumora Therapeutics (NASDAQ:NMRA) Will Use Its Cash Wisely
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Neumora: Phase 3 MDD Readout In H2-24 Could Get Ball Rolling
Summary Results from the phase 3 KOASTAL-1 study, using Navacaprant for the treatment of patients with Major Depressive Disorder, expected in the 2nd half of 2024. The global Major Depressive Disorder [MDD] treatment market is estimated to reach $14.96 billion by 2032. Company hopes to differentiate itself against other MDD drugs in that Navacaprant has a novel MOA, no side effects seen in approved drugs and treat patients not yet helped. Navacaprant is versatile in that it is believed it could also be used to treat patients with bipolar depression; initiation of phase 2 bipolar depression study using this drug expected in the 1st half of 2024. Read the full article on Seeking AlphaRentabilidad de los accionistas
| NMRA | US Pharmaceuticals | Mercado US | |
|---|---|---|---|
| 7D | -20.6% | -3.4% | -0.9% |
| 1Y | -31.6% | 45.9% | 13.9% |
Rentabilidad vs. Industria: Los resultados de NMRA fueron inferiores a los de la industria US Pharmaceuticals, que obtuvo un rendimiento del 45.9% el año pasado.
Rentabilidad vs. Mercado: NMRA obtuvo unos resultados inferiores a los del mercado US, que fueron del 13.9% el año pasado.
Volatilidad de los precios
| NMRA volatility | |
|---|---|
| NMRA Average Weekly Movement | 26.4% |
| Pharmaceuticals Industry Average Movement | 8.6% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 15.3% |
| 10% least volatile stocks in US Market | 2.9% |
Precio estable de las acciones: El precio de las acciones de NMRA ha sido volátil durante los últimos 3 meses en comparación con el mercado US.
Volatilidad a lo largo del tiempo: La volatilidad semanal de NMRA ha aumentado de 18% a 26% en el último año.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 2019 | 63 | Josh Pinto | www.neumoratx.com |
Neumora Therapeutics, Inc, empresa biofarmacéutica en fase clínica, se dedica a desarrollar tratamientos terapéuticos para enfermedades cerebrales, trastornos neuropsiquiátricos y enfermedades neurodegenerativas en Estados Unidos. La empresa desarrolla navacaprant (NMRA-140), un nuevo antagonista oral de los receptores opiáceos kappa que se administra una vez al día y que se encuentra en ensayos clínicos de fase 3 para el tratamiento del trastorno depresivo mayor. También desarrolla NMRA-511, que se halla en ensayos clínicos de fase 1b en pacientes con agitación asociada a demencia por enfermedad de Alzheimer; y NMRA-861 y NMRA-898, moduladores alostéricos positivos (PAM) de receptores muscarínicos M4 para la esquizofrenia y otros trastornos neuropsiquiátricos.
Resumen de fundamentos de Neumora Therapeutics, Inc.
| Estadísticas fundamentales de NMRA | |
|---|---|
| Capitalización bursátil | US$195.41m |
| Beneficios(TTM) | -US$212.74m |
| Ingresos (TTM) | n/a |
¿Está NMRA sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de NMRA | |
|---|---|
| Ingresos | US$0 |
| Coste de los ingresos | US$0 |
| Beneficio bruto | US$0 |
| Otros gastos | US$212.75m |
| Beneficios | -US$212.74m |
Últimos beneficios comunicados
Jun 30, 2026
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | -1.13 |
| Margen bruto | 0.00% |
| Margen de beneficio neto | 0.00% |
| Ratio deuda/patrimonio | 118.9% |
¿Cómo se ha desempeñado NMRA a largo plazo?
Ver rendimiento histórico y comparativaAnálisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/09/14 08:19 |
| Precio de las acciones al final del día | 2026/09/11 00:00 |
| Beneficios | 2026/06/30 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Neumora Therapeutics, Inc. está cubierta por 10 analistas. 9 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Yatin Suneja | Guggenheim Securities, LLC |
| Douglas Tsao | H.C. Wainwright & Co. |
| Tessa Romero | J.P. Morgan |